Protein & Cell >

2019 , Vol. 10 >Issue 11: 840 - 845

DOI: https://doi.org/10.1007/s13238-019-0642-z

LETTER

Analysis of VISTA expression and function in renal cell carcinoma highlights VISTA as a potential target for immunotherapy

  • Shanjuan Hong 1 ,
  • Qing Yuan 2 ,
  • Haizhui Xia 3 ,
  • Genzhen Zhu 1 ,
  • Yu Feng 1 ,
  • Qiang Wang 4 ,
  • Zhiyin Zhang 3 ,
  • Wei He 3 ,
  • Jian Lu , 3 ,
  • Chen Dong , 1,5 ,
  • Ling Ni , 1
Expand
  • 1. Institute for Immunology and School of Medicine, Tsinghua University, Medical Research Building, Beijing 100084, China
  • 2. Division of Urology, The 8th Medical Center of Chinese PLA General Hospital, Beijing 100091, China
  • 3. Department of Urology, Peking University Third Hospital, Beijing 100191, China
  • 4. Department of Urology, School of Clinical Medicine, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing 102218, China
  • 5. Beijing Key Lab for Immunological Research on Chronic Diseases, Beijing 100084, China

Published date: 15 Nov 2019

Copyright

2019 The Author(s) 2019
Fold

Cite this article

Shanjuan Hong , Qing Yuan , Haizhui Xia , Genzhen Zhu , Yu Feng , Qiang Wang , Zhiyin Zhang , Wei He , Jian Lu , Chen Dong , Ling Ni . Analysis of VISTA expression and function in renal cell carcinoma highlights VISTA as a potential target for immunotherapy[J]. Protein & Cell, 2019 , 10(11) : 840 -845 . DOI: 10.1007/s13238-019-0642-z

References

Publishing order | Descend order by publishing year | Descend order by cited within
1
Callahan MK, Postow MA, Wolchok JD (2016) Targeting T cell coreceptors for cancer therapy. Immunity 44:1069–1078

DOI

2
Finke JH, Rayman P, Edinger M, Tubbs RR, Stanley J, Klein E, Bukowski R (1992) Characterization of a human renal cell carcinoma specific cytotoxic CD8+ T cell line. J Immunother 1991 (11):1–11

DOI

3
Lines JL, Pantazi E, Mak J, Sempere LF, Wang L, O’Connell S, Ceeraz S, Suriawinata AA, Yan S, Ernstoff MS (2014) VISTA is an immune checkpoint molecule for human Tcells. Cancer Res 74:1924–1932

DOI

4
Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE III, Koeppen H, Astarita JL, Cubas R (2018) TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554:544–548

DOI

5
McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O, Powderly JD, Infante JR, Fasso M, Wang YV (2016) Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol 34:833–842

DOI

6
Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF(2015) Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 33:1430–1437

DOI

7
Ni L, Dong C (2017a) New B7 family checkpoints in human cancers. Mol Cancer Ther 16:1203–1211

DOI

8
Ni L, Dong C (2017b) New checkpoints in cancer immunotherapy. Immunol Rev 276:52–65

DOI

9
Sittig SP, Kollgaard T, Gronbaek K, Idorn M, Hennenlotter J, Stenzl A, Gouttefangeas C, Thor Straten P (2013) Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes. Oncoimmunology 2:e26014

DOI

10
Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S, Kiialainen A, Hanhart J, Schill C, Hess C (2018) A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med 24:994–1004

DOI

11
Wang L, Rubinstein R, Lines JL, Wasiuk A, Ahonen C, Guo Y, Lu LF, Gondek D, Wang Y, Fava RA (2011) VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med 208:577–592

DOI

12
Xie S, Huang J, Qiao Q, Zang W, Hong S, Tan H, Dong C, Yang Z, Ni L (2018) Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors. Cancer Immunol Immunother 67:1685–1694

DOI

13
Yu JW, Bhattacharya S, Yanamandra N, Kilian D, Shi H, Yadavilli S, Katlinskaya Y, Kaczynski H, Conner M, Benson W (2018) Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments. PLoS ONE 13: e0206223

DOI

Options
Outlines

/

〈 〉